Head to Head Review: OncoGenex Pharmaceuticals (ACHV) & The Competition
OncoGenex Pharmaceuticals (NASDAQ: ACHV) is one of 198 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its rivals? We will compare OncoGenex Pharmaceuticals to similar businesses based on the strength of its analyst recommendations, risk, earnings, institutional ownership, dividends, valuation and profitability.
This is a breakdown of current recommendations and price targets for OncoGenex Pharmaceuticals and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|OncoGenex Pharmaceuticals Competitors||477||2261||6178||119||2.66|
As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.12%. Given OncoGenex Pharmaceuticals’ rivals higher probable upside, analysts clearly believe OncoGenex Pharmaceuticals has less favorable growth aspects than its rivals.
Valuation and Earnings
This table compares OncoGenex Pharmaceuticals and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|OncoGenex Pharmaceuticals Competitors||$207.79 million||-$2.30 million||0.67|
OncoGenex Pharmaceuticals’ rivals have higher revenue, but lower earnings than OncoGenex Pharmaceuticals. OncoGenex Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
48.7% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 35.8% of OncoGenex Pharmaceuticals shares are held by company insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This table compares OncoGenex Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|OncoGenex Pharmaceuticals Competitors||-3,945.41%||-117.30%||-43.55%|
Risk & Volatility
OncoGenex Pharmaceuticals has a beta of 1.98, suggesting that its share price is 98% more volatile than the S&P 500. Comparatively, OncoGenex Pharmaceuticals’ rivals have a beta of 1.63, suggesting that their average share price is 63% more volatile than the S&P 500.
About OncoGenex Pharmaceuticals
Achieve Life Sciences, Inc., formerly OncoGenex Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company’s segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States. The Company’s product candidates include Custirsen, Apatorsen and OGX-225. The Company is focused on targeting these particular proteins to disable the tumor cell’s adaptive defenses, thereby rendering the tumor cells susceptible to attack with a range of cancer therapies. Of these product candidates, Custirsen and Apatorsen are clinical-stage assets. Custirsen is being evaluated in two Phase III trials. Apatorsen is a product candidate designed to inhibit production of heat shock protein 27 (Hsp27).
Receive News & Ratings for OncoGenex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoGenex Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.